These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 9031607)

  • 1. Association of natural killer cell immune recovery with a graft-versus-leukemia effect independent of graft-versus-host disease following allogeneic bone marrow transplantation.
    Jiang YZ; Barrett AJ; Goldman JM; Mavroudis DA
    Ann Hematol; 1997 Jan; 74(1):1-6. PubMed ID: 9031607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
    Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
    Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of graft-versus-host disease by phenotypic analysis of early immune reconstitution after CD6-depleted allogeneic bone marrow transplantation.
    Soiffer RJ; Gonin R; Murray C; Robertson MJ; Cochran K; Chartier S; Cameron C; Daley J; Levine H; Nadler LM
    Blood; 1993 Oct; 82(7):2216-23. PubMed ID: 7691252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A decrease in graft-vs.-host disease without loss of graft-vs.-leukemia reactivity after MHC-matched bone marrow transplantation by selective depletion of donor NK cells in vivo.
    Johnson BD; Truitt RL
    Transplantation; 1992 Jul; 54(1):104-12. PubMed ID: 1631918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Administration of interleukin-7 after allogeneic bone marrow transplantation improves immune reconstitution without aggravating graft-versus-host disease.
    Alpdogan O; Schmaltz C; Muriglan SJ; Kappel BJ; Perales MA; Rotolo JA; Halm JA; Rich BE; van den Brink MR
    Blood; 2001 Oct; 98(7):2256-65. PubMed ID: 11568014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of GVHD on the recovery of NK cell activity and LAK precursors following BMT.
    Keever CA; Klein J; Leong N; Copelan EA; Avalos BR; Kapoor N; Cunningham I; Tutschka PJ
    Bone Marrow Transplant; 1993 Sep; 12(3):289-95. PubMed ID: 8241989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Graft-versus-leukaemia activity can be predicted by natural cytotoxicity against leukaemia cells.
    Glass B; Uharek L; Zeis M; Loeffler H; Mueller-Ruchholtz W; Gassmann W
    Br J Haematol; 1996 May; 93(2):412-20. PubMed ID: 8639441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic MHC-mismatched activated natural killer cells administered after bone marrow transplantation provide a strong graft-versus-leukaemia effect in mice.
    Zeis M; Uharek L; Glass B; Steinmann J; Dreger P; Gassmann W; Schmitz N
    Br J Haematol; 1997 Mar; 96(4):757-61. PubMed ID: 9074419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The graft-versus-leukemia (GVL) phenomenon: is GVL separable from GVHD?
    Slavin S; Ackerstein A; Naparstek E; Or R; Weiss L
    Bone Marrow Transplant; 1990 Sep; 6(3):155-61. PubMed ID: 2252954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes of lymphocyte subsets in leukemia patients who received allogenic bone marrow transplantation.
    Komatsuda M
    Acta Med Okayama; 1991 Aug; 45(4):257-65. PubMed ID: 1683740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation.
    Teshima T; Hill GR; Pan L; Brinson YS; van den Brink MR; Cooke KR; Ferrara JL
    J Clin Invest; 1999 Aug; 104(3):317-25. PubMed ID: 10430613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
    Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
    J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma.
    Fowler DH; Gress RE
    Leuk Lymphoma; 2000 Jul; 38(3-4):221-34. PubMed ID: 10830730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune reconstitution in patients with Fanconi anemia after allogeneic bone marrow transplantation.
    Perlingeiro Beltrame M; Malvezzi M; Bonfim C; Covas DT; Orfao A; Pasquini R
    Cytotherapy; 2014 Jul; 16(7):976-89. PubMed ID: 24831839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-15 enhances immune reconstitution after allogeneic bone marrow transplantation.
    Alpdogan O; Eng JM; Muriglan SJ; Willis LM; Hubbard VM; Tjoe KH; Terwey TH; Kochman A; van den Brink MR
    Blood; 2005 Jan; 105(2):865-73. PubMed ID: 15280205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allospecific CD8+ Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease.
    Fowler DH; Breglio J; Nagel G; Eckhaus MA; Gress RE
    J Immunol; 1996 Dec; 157(11):4811-21. PubMed ID: 8943383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose donor CD8+ cells in the CD4-depleted graft prevent allogeneic marrow graft rejection and severe graft-versus-host disease for chronic myeloid leukemia patients in first chronic phase.
    Gallardo D; García-López J; Sureda A; Canals C; Ferra C; Cancelas JA; Berlanga JJ; Brunet S; Boqué C; Picón M; Torrico C; Amill B; Martino R; Martínez C; Martín-Henao G; Domingo-Albós A; Grañena A
    Bone Marrow Transplant; 1997 Dec; 20(11):945-52. PubMed ID: 9422473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets.
    Johnson BD; Becker EE; Truitt RL
    Biol Blood Marrow Transplant; 1999; 5(3):123-32. PubMed ID: 10392958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Donor natural killer (NK1.1+) cells do not play a role in the suppression of GVHD or in the mediation of GVL reactions after DLI.
    Johnson BD; Dagher N; Stankowski WC; Hanke CA; Truitt RL
    Biol Blood Marrow Transplant; 2001; 7(11):589-95. PubMed ID: 11760146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of graft-versus-host disease by selective depletion of CD6-positive T lymphocytes from donor bone marrow.
    Soiffer RJ; Murray C; Mauch P; Anderson KC; Freedman AS; Rabinowe SN; Takvorian T; Robertson MJ; Spector N; Gonin R
    J Clin Oncol; 1992 Jul; 10(7):1191-200. PubMed ID: 1607923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.